Harlequin ichthyosis (HI) is a rare and severe form of congenital ichthyosis. Linked to deletion and truncation mutations of a keratinocyte lipid transporter, HI is characterized by diffuse epidermal hyperkeratinization and defective desquamation. At birth, the HI phenotype is striking with thick hyperkeratotic plate-like scales with deep dermal fissures, severe ectropion and eclabium, among other findings. Over the first months of life, the hyperkeratotic covering is shed, revealing a diffusely erythematous, scaly epidermis, which persists for the remainder of the patient's life. Although HI infants have historically succumbed in the perinatal period related to their profound epidermal compromise, the prognosis of HI infants has vastly improved over the past 20 years. Here, we report a case of HI treated with acitretin, focusing on the multi-faceted management of the disease in the inpatient setting. A review of the literature of the management of HI during the perinatal period is also presented.
Introduction
Harlequin ichthyosis (HI) is the rarest and the most severe form of congenital ichthyosis. Inherited in an autosomal recessive manner, HI is primarily associated with mutations causing functional defects in the keratinocyte lipid transporter adenosine triphosphatebinding cassette A12. 1, 2 Dysfunctional or absent adenosine triphosphate-binding cassette A12 protein causes a disturbance in lamellar granule lipid and protease transport in granular layer keratinocytes, resulting in epidermal hyperkeratinization and defective desquamation. 3, 4 At birth, neonates with HI are covered by a thick hyperkeratotic plate-like covering of stratum corneum with deep dermal fissures. Other findings common with this disorder include severe ectropion and eclabium, alopecia, digital contractures and growth delays. Over the first months of life, the hyperkeratotic covering is shed, leaving the skin diffusely erythematous and scalyFphenotypically suggestive of nonbullous congenital icthyosiform erythroderma. This latter presentation dominates for the remainder of the patient's life.
Infants with HI have historically succumbed in the perinatal period to sepsis, respiratory failure and infections, poor nutrition and electrolyte imbalances. In the past 20 years, however, the prognosis of HI infants has improved due to advances in neonatal intensive care and targeted oral retinoid therapy. Despite this, little has been reported about the daily management of HI infants during the early inpatient stage. We report a case of HI treated with acitretin focusing on the multi-faceted management of the disease in the inpatient setting. Given the rareness of the disease and the lack of treatment guidelines, we hope that our experience may be of use to assist future teams taking care of these special patients.
Case
The 34 6 7 -week Hispanic male infant was delivered at an outside hospital by cesarean section (due to repeat) after premature rupture of membranes. He was born to a nonconsanguinous couple with no family history of skin disorders or previous children with skin disorders. He had an uncomplicated prenatal course except the fetal ultrasound was interpreted as showing facial and extremity abnormalities. His APGAR scores were 5 and 9 at 1 and 5 min, respectively. He weighed 2.58 kg at birth.
At delivery, he was noted to have generalized edema with thick hyperkeratotic plates over his entire body and scalp and associated deep erythematous fissures (Figure 1 ). His face was distorted as a result of taut scales and his ears were bound to the scalp by tight keratinous skin obscuring the pinnae (Figure 2 ). He also had severe ectropion, eclabium and diffuse alopecia. His hands and feet were tight and edematous with contracted digits showing dusky tapering at distal ends and decreased capillary refill. He had diffuse decreased range of motion, especially in the digits, wrists, elbows, knees and ankles secondary to skin tautness. As it was unnecessary for diagnosis, histopathology was not performed.
The infant was transferred to our neonatal intensive care unit within hours of delivery. The patient was followed by a medical team consisting of neonatologists, dermatologists (consulted day of life (DOL) 1), infectious disease specialist (consulted DOL 11), plastic surgeons (consulted DOL 7) and ophthalmologists (consulted DOL 2). He was also cared for by ancillary staff including physical and occupational therapist, social workers, nutritionists and nurses. Key elements of the treatment plan during the neonatal period included skin care, sepsis monitoring and treatment, pain control, and management of ectropion and digital contractures.
The patient was stable from birth on room air, but was maintained in a mist tent for several weeks. He was quickly transitioned from nothing by mouth and total parenteral nutrition to his goal enteral feeds by DOL 8. Owing to his increased metabolic demands, he initially was fed a 26 kcal formula, but he was transitioned to a standard premature infant (22 kcal) formula before discharge.
On DOL 1, the patient was started on acitretin (1 mg kg À1 per day) with regular monitoring of liver function tests, lipids, triglycerides and complete blood count. In addition to pharmacotherapy, white petrolatum was applied over the entire body surface every 6 h. Other topical medications or preparations were avoided because of the likelihood of systemic absorption and concerns about their ophthalmic safety in light of the bilateral ectropion. Bathing of the patient was limited to once daily with normal saline. After several weeks, the patient started shedding the thick hyperkeratotic plates revealing skin consistent with generalized erythematous ichthyosis. Plates of scale on the trunk and appendages were essentially resolved by DOL 30, whereas moist scale remained longer on the face and scalp.
On DOL 13, he was noted to have a murmur and tachycardia. He received his first blood transfusion on that day and a second on DOL 25 due to a hematocrit of 29.4 (normal range 31 to 55). He was started on a multivitamin with iron for anemia of premature, which was discontinued due to stable hematocrits before discharge. An echocardiogram on DOL 13 showed a mild pulmonary artery stenosis and a left-to-right shunt through the atria consistent with either a patent foramen ovale or an atrial septal defect. A repeat echocardiogram on DOL 27 showed a patent foramen ovale, which was monitored clinically without further intervention.
Given the patient's increased susceptibility to sepsis and a persistent mild tachycardia, the patient was immediately started on ampicillin and gentamicin after delivery until initial blood cultures were confirmed negative at 48 h. The patient was closely monitored for sepsis with a low threshold for sepsis work-up for the duration of his inpatient stay. Strict protective precautions were observed by the treatment team and visitors at all times to reduce iatrogenic infections. Despite these efforts, the patient had positive blood cultures multiple times during the hospitalization including Candida albicans, coagulase-negative Staphylococcus sensitive only to vancomycin and Klebsiella oxygtoca. The patient was started on prophylactic fluconazole and penicillin VK on DOL 27. After a 6-week course, the fluconazole was discontinued and he remains on penicillin VK indefinitely. In addition to systemic infections, he was treated for three episodes of conjunctivitis. Gram-positive and -negative rods (not further identified) grew on culture of purulent eye discharge on DOL 27. He was treated with As pain secondary to truncal fissures discourages deep breathing and increases the risk of pulmonary complications, pain management was achieved on transfer to our institution at DOL 1 with fentanyl at 2 mg kg À1 intravenously every 2 h and adjunctive sucrose sips as needed. After several weeks, his pain medications changed to acetaminophen every 6 h for the remainder of the hospitalization. Ophthalmology recommended Lacri-lube every hour to both eyes to manage the ectropion and prevent secondary keratitis. Plastic surgery recommended conservative management of digital contractures with thin sterile gauze rolls be placed in the palms and soles to prevent contracture progression and daily physical therapy to promote digital and joint movement. In addition, soft splinting of the hands/feet encouraged gradual digital extension between physical therapy sessions. No specific treatment was required for eclabium. On DOL 33, he failed his bilateral newborn hearing test. More detailed testing on DOL 83 revealed a conductive hearing loss. After saline drops were applied to both external auditory canals for several days, improvement in the deficit was noted on DOL 96, but he did not achieve normal hearing while he was an inpatient. Genetics was consulted on DOL 6 and discussed the inherited nature of HI with the parents. The parents declined genetic testing, as they did not plan to have additional children.
The patient was transferred to a community hospital closer to the family's home on DOL 39 where he was stable and similar intensive medical care continued. He received his routine premature vaccinations roughly on schedule including Hepatitis B, Respiratory Syncytial Virus, Diphtheria Tetanus Pertussis, Inactivated Polio, Haemophilus influenza and Pneumococcal (conjugate). On DOL 72, he was changed from Lacri-lube to carboxymethocel.
On DOL 105, the patient was discharged home. The patient received hourly home sessions of physical therapy twice weekly and occupational therapy once weekly. During these sessions they worked on range of motion exercises, movement initiation and fine motor skills. The parents continued to apply white petrolatum to the patient's entire skin surface four times a day for the first year of life. In addition, they placed carboxymethocel in his eyes every 3 h while awake. The patient was bathed daily with phisoderm. Over the year, acitretin was tapered from 0.5 to 0.2 mg kg À1 per day dosed on every third day. At 6 months of life, tazoratene 0.1% cream was added for application to the scalp, elbows, knees, palms and soles. The patient remained on antimicrobial prophylaxis with penicillin VK twice daily. By 6 months of age, the ectropion improved enough to permit closure of his eyes when sleeping; plans for surgical correction of the ectropion were delayed given this improvement. He continues to have a conductive hearing loss and be followed by otolaryngology. At 1 year of life he was in the 15th percentile for height, less than 5th percentile for weight and 10th percentile for head circumference. According to his physical therapist, the patient is physically able (not limited by his skin) to achieve developmental milestones but these are greatly delayed by his apprehensions about independent or assisted movement. At age of 18 months, the patient was unable to sit, crawl or walk. The importance of daily physical and occupational exercises done with family members was stressed to the parents. The patient is now 2 years old and able to run, jump and talk. He continues to be followed by physical and occupational therapy, dermatology, ophthalmology and otolaryngology along with his primary care physician.
Discussion
Harlequin ichthyosis is a rare genetic disorder characterized by defective keratinization and desquamation of the epidermis. The genetic mutations underlying HI result in dysfunction of adenosine triphosphate-binding cassette A12, a protein involved in intracellular lipid transport, and cause abnormal lamellar granule secretion in the epidermis. 2, 3, 5 Consequently, important lipids and proteases are not secreted into the interstitial space between granular layer keratinocytes. The absence of interstitial lipid delivery results in a profoundly abnormal epidermal permeability barrier and increased transcutaneous water losses. 6 The body responds by stimulating cytokine cascades and epidermal hyperplasia, which, in turn, results in the epidermal hyperkeratosis and inflammation characteristic of HI. 7 Likewise, it has been theorized that a concomitant absence of interstitial proteases prevents corneodesmosomes that link superficial keratinocytes to underlying keratinocytes from being digested. 4, 7 As a result, these superficial keratinocytes are unable to undergo normal desquamation, which results in the accumulation of stratum corneum.
Abnormal desquamation dominates the early neonatal phenotype of HI, which is manifested by a thick, plate-like encasement of accumulated stratum corneum. The rigid covering contains numerous erythematous fissures that reach deep into the dermis, which dramatically increases susceptibility to infection. Other early findings associated with HI, including ectropion and eclabium, are attributable to the restrictions in mobility and development caused by the rigid epidermal encasement. As the HI newborn experiences terrestrial life, the body senses the profound epidermal barrier defect caused by the paucity of lipids in the epidermal interstitial space and responds by attempting to repair the defect through massive epidermal hyperplasia. A dramatic phenotypic shift ensues, characterized by shedding of the rigid stratum corneum encasing the body. An underlying epidermal surface of diffuse erythema with fine scaling is revealed. This differing cutaneous phenotype, which most resembles nonbullous congenital icthyosiform erythroderma, dominates the remainder of the patient's life. 8 The nonbullous congenital icthyosiform erythroderma-like phenotype offers moreFbut by no means normalFepidermal protection (Figure 3 ). In fact, the importance of systemic retinoids, a key therapy for HI, is largely due to their ability to accelerate the shedding of the hyperkeratotic encasement, promoting the phenotypic shift.
Early management of HI generally includes a humidified incubator, temperature regulation, nutrition replacement, skin and eye care, pain control, physiotherapy, and infection control. A humidified incubator with strict temperature regulation is essential for mitigating the large transcutaneous losses of water and heat caused by the dysfunctional epidermal permeability barrier. Even in the incubator setting, these losses, compounded by chronic inflammation, constitute a significant caloric drain for HI infants and can lead to growth retardation if calories are not replaced. Consequently, nutritional supplementation is essential in HI neonates, who can require as much as 25% more calories per day than comparable neonates. 6, 9 Skin care is also a constant focus in these patients. Emollients should be generously applied to the skin multiple times per day to provide the infant with protection against foreign pathogens and help prevent transcutaneous water loss. However, given the compromised epidermal barrier and the likelihood of systemic absorption, other topical treatments should be chosen wisely. Topical keratinolytics frequently used in adulthood (salicylic acid, alpha hydroxyl acids and urea) are not appropriate in the neonatal period due to potential systemic toxicity from increased cutaneous absorption. Moreover, as systemic retinoid therapy achieves adequate keratinolysis, these potentially toxic topical agents are largely unnecessary. Lastly, bathing and soaking can reduce the risks of skin infection, replenish moisture in the skin and promote the softening and shedding of the thick stratum corneum.
The deep cutaneous fissures of HI are very painful, making pain management an important issue in the care of these patients. Acutely, pain associated with truncal fissures discourages deep breathing and increases the risk of pulmonary complications. In the long term, inadequate neonatal pain control has been associated with developmental delay and abnormal stressor responses. [10] [11] [12] However, it is important to balance pain and over-sedation as an over-medicated neonate can have feeding issues and suffer respiratory depression.
Some of the other co-morbidities associated with HI may require consultation with other medical specialists. Ectropion is a common feature associated with HI and is present in all of the cases described in the literature. Although management of ectropion is best handled by ophthalmologists, perinatal care teams can initiate treatment with artificial tears (Lacri-lube) applied to the eye and exposed conjunctiva every 2 h and antibiotic ointment until ophthalmologist can be consulted. Hand contractures, another complication associated with HI, may require a surgical consult, as gangrene of the distal digits can occur if contractures go untreated. In addition, physiotherapy is an important aspect of early and long-term care, as it decreases contractures and promotes increased range of motion of joints.
As true in our patient, sepsis remains a constant threat in the first month before the deep fissures have healed and continues to be a leading cause of death in these patients throughout infancy. For this reason, close monitoring for signs of sepsis and aggressive treatment of bacterial or fungal infections are essential. In light of this risk, some treatment teams have gone beyond heightened surveillance, favoring prophylactic treatment. Although antibiotic and/or antifungal prophylaxis may seem intuitive in patients with severely compromised skin barriers like those of HI, there exists little clinical evidence for such prophylaxis. Although no studies deal with HI directly, the appropriateness of antibiotic prophylaxis has been studied in burn patients with similar barrier compromise. These studies indicate that antibiotic prophylaxis in childhood burns does not reduce the rate of wound infection or subsequent sepsis. [13] [14] [15] In fact, antibiotic prophylaxis may even be detrimental by favoring the growth of P. aeruginosa in burn wounds and enhancing the risk of candidemia. 15 Of interest, in one of the HI cases reported in which antibiotic prophylaxis was administered, the HI infant died on day 21 from a systemic infection with P. aeruginosa.
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Antifungal prophylaxis has also been debated in neonatal burn populations. Compelling evidence suggests that topical prophylaxis with nystatin significantly reduces the incidence of Candida wound infection and systemic candidiasis in burn patients. 17 In contrast, the value of systemic antifungal prophylaxis has not been shown in burn patients. 18 There is, however, compelling data showing the incidence of re-infection, and subsequent death, is much higher for patients who have had a confirmed episode of Candida wound infection. 18, 19 Thus, longer courses of antifungal treatment or even systemic prophylaxis may benefit HI infants with confirmed Candida wound infection. Nevertheless, the impaired barrier of burn patients is distinct from that of HI patients and a direct correlation cannot be implied.
Systemic retinoids have become a mainstay of therapy in disorders of keratinization, and HI is no exception. 20 In neonates with HI, early use of systemic retinoids promotes accelerated shedding of the hyperkeratotic plates, whereas continued use reduces scale and improves ectropion and eclabium. 
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Retinoids should be started as soon after delivery as possible. The particular retinoid therapy and doses chosen by previous teams are shown in Table 1 . Acitretin has become the preferred retinoid because its shorter half-life provides a better safety profile. 20 Moreover, acitretin when compared with etretinate has been associated with reduced severity of side effects, including less severe headaches, mucocutaneous dryness and skin irritation. 20, 21 Furthermore, etretinate has been off the market in the United States since 2001. As alterations of lipids and liver function tests can be seen with the use of retinoids including acitretin, pre-therapeutic assessment and occasional monitoring of a complete blood count, urea, liver function tests, creatinine, cholesterol, triglyceride levels and urinalysis is necessary. Toxic, irreversible musculoskeletal side effects (including osteoporosis, periosteal plucking, slender long bones and premature epiphyseal closure) have been associated with chronic use of high-dose systemic retinoids. However, these adverse musculoskeletal side effects have not been associated with lower doses typically used to treat HI and other forms of ichthyosis, even when used for periods greater than 10 years. 21 Despite the low risk of complications, it is important to titrate the patient to the lowest effective dose of acitretin over the first year of life to minimize musculoskeletal side effects. In addition to blood work mentioned above, periodic monitoring of vitamin D levels in HI infants may be warranted, as a recent report suggests an increased incidence of vitamin D deficiencies in patients with congenital ichthyosis. 22 The role of the medical team must go beyond optimizing the physical health of the patient to include issues affecting the parental bonding and home life. The appearance of the HI neonate is striking and intimidating for seasoned medical practitioners, much less expectant parents. Thus, it is important to assemble the appropriate medical team early including a dermatologist, geneticist and pediatric intensivist who can meet with parents to discuss their concerns and provide them with a sense of life after discharge. Given the appearance of the neonate, it is not uncommon for parents to harbor profound feelings of guilt, shame or grief. One mother even considered suicide because she was unable to face the prospect of raising a child with HI. 23 In other cases, this has manifested as neglect of the child by the parents after discharge, that is, refusing to take the child out of the house. 23 With this in mind, parents might benefit from speaking with a mental health specialist or counselor about their feelings and fears during the newborn's inpatient stay. Also, parent-child interaction in the early neonatal period, particularly skin-to-skin contact, has been repeatedly shown to be essential for building the foundation of the parent-child relationship. To foster this bonding and reduce parental fears of harming their infants through casual contact, parents should be encouraged to participate in their newborn's care. 24, 25 Parents can be readily trained to apply emollients to their infant's skin and to aid with baths. Breastfeeding should also be encouraged. Though restrictions associated with the rigid epidermal covering may preclude breast feeding early on, HI infants treated with systemic retinoids have been reported to effectively suckle after 2 weeks of treatment. 9 By fostering parental bonding and addressing issues of acceptance while the newborn is still an inpatient, the medical team can help ensure that parents are psychologically prepared to take over care when the infant is discharged. Lastly, as the day-to-day management of HI remains complex even after discharge, it is important that a social worker be involved early to help structure a comprehensive discharge plan that will provide the caretakers with support during the transition from hospital to home. 26 In summary, HI is a severe disorder of the skin that presents a formidable challenge for even the most skilled perinatal teams. Nevertheless, we believe that the complex management of these patients can be best achieved by using a multidisciplinary approach characterized by strong communication, both among the medical team and with the family. Although HI is very rare, with the exception of oral retinoids, the general treatment approach reviewed above could be implemented in the management of other disorders of keratinization affecting neonates.
